Growth Hormone Treatment, Acromegaly, and Relationship to Cancer and Leukemia

1994 ◽  
pp. 259-268
Author(s):  
Louis E. Underwood
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Hormone Treatment

Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans

Diabetes ◽  
1993 ◽  
Vol 42 (7) ◽  
pp. 1082-1085 ◽  
Author(s):  
S. E. Kahn ◽  
F. F. Horber ◽  
R. L. Prigeon ◽  
M. W. Haymond ◽  
D. Porte
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Hormone Treatment

Two Years of Growth Hormone Treatment in the First Growth Hormone Deficient Patient with Cerebrofaciothoracic Dysplasia

2006 ◽  
Vol 19 (9) ◽  
Author(s):  
C. Kanaka-Gantenbein ◽  
H. Fryssira ◽  
K. Kakavakis ◽  
E. Bouzas ◽  
L. Thomaidis ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Deficient Patient

scholarly journals Patient preferences for growth hormone treatment in Japanese children

2021 ◽  
Author(s):  
Toshiaki Tanaka ◽  
Takahiro Sato ◽  
Akira Yuasa Mhwm ◽  
Takeshi Akiyama ◽  
Adeeb Tawseef
Keyword(s):  
Growth Hormone ◽  
Patient Preferences ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Japanese Children

scholarly journals Effects of Childhood Multidisciplinary Care and Growth Hormone Treatment on Health Problems in Adults with Prader-Willi Syndrome

2021 ◽  
Vol 10 (15) ◽  
pp. 3250
Author(s):  
Karlijn Pellikaan ◽  
Anna G. W. Rosenberg ◽  
Kirsten Davidse ◽  
Anja A. Kattentidt-Mouravieva ◽  
Rogier Kersseboom ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Multidisciplinary Care ◽  
Hormone Treatment ◽  
Health Problems ◽  
Pituitary Hormone ◽  
Childhood And Adolescence ◽  
Prader Willi Syndrome ◽  
Adult Age ◽  
Beneficial Effects

Prader-Willi syndrome (PWS) is a complex hypothalamic disorder. Features of PWS include hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies. The combination of growth hormone treatment and multidisciplinary care (GHMDc) has greatly improved the health of children with PWS. Little is known about the effects of childhood GHMDc on health outcomes in adulthood. We retrospectively collected clinical data of 109 adults with PWS. Thirty-nine had received GHMDc during childhood and adolescence (GHMDc+ group) and sixty-three had never received growth hormone treatment (GHt) nor multidisciplinary care (GHMDc− group). Our systematic screening revealed fewer undetected health problems in the GHMDc+ group (10%) than in the GHMDc− group (84%). All health problems revealed in the GHMDc+ group had developed between the last visit to the paediatric and the first visit to the adult clinic and/or did not require treatment. Mean BMI and the prevalence of diabetes mellitus type 2 were significantly lower in the GHMDc+ group compared to the GHMDc− group. As all patients who received GHt were treated in a multidisciplinary setting, it is unknown which effects are the result of GHt and which are the result of multidisciplinary care. However, our data clearly show that the combination of both has beneficial effects. Therefore, we recommend continuing GHMDc after patients with PWS have reached adult age.

Sign in / Sign up

Export Citation Format

Share Document